# AdventHealth Orlando

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/adventhealth-orlando/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 42.8 |
| Citations | 183,028 |
| City | Orlando |
| Country | US |
| Description | AdventHealth Orlando is a research organisation in Orlando, US. OpenAlex records 5,027 works and 183,028 citations for it. 1,863 researchers list it as their most recent affiliation. |
| Homepage | https://www.adventhealth.com/hospital/adventhealth-orlando |
| OpenAlex ID | https://openalex.org/I2799648416 |
| Region | Florida |
| Researchers | 1,863 |
| ROR ID | https://ror.org/02n1cyj49 |
| Type | healthcare |
| Wikidata ID | https://www.wikidata.org/wiki/Q3145309 |
| Works | 5,027 |

## University papers

Showing 12 of 17.

- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer](https://scholariq.org/papers/first-line-crizotinib-versus-chemotherapy-in-i-alk-i-positive-lung-cancer/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial](https://scholariq.org/papers/alectinib-in-alk-positive-crizotinib-resistant-non-small-cell-lung-cancer-a/)
- [Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study](https://scholariq.org/papers/alectinib-in-crizotinib-refractory-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023](https://scholariq.org/papers/burden-of-375-diseases-and-injuries-risk-attributable-burden-of-88-risk-factors/)
- [Understanding the Cellular and Molecular Mechanisms of Physical Activity-Induced Health Benefits](https://scholariq.org/papers/understanding-the-cellular-and-molecular-mechanisms-of-physical-activity-induced/)
- [Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023](https://scholariq.org/papers/global-burden-of-292-causes-of-death-in-204-countries-and-territories-and-660/)
- [Reduced physical activity increases intermuscular adipose tissue in healthy young adults](https://scholariq.org/papers/reduced-physical-activity-increases-intermuscular-adipose-tissue-in-healthy/)
- [Advancing the use of<i>Lactobacillus acidophilus</i>surface layer protein A for the treatment of intestinal disorders in humans](https://scholariq.org/papers/advancing-the-use-of-i-lactobacillus-acidophilus-i-surface-layer-protein-a-for/)
- [Post‐traumatic Splenic Injury Outcomes for Nonoperative and Operative Management: A Systematic Review](https://scholariq.org/papers/post-traumatic-splenic-injury-outcomes-for-nonoperative-and-operative-management/)
- [A rare case of sinus of valsalva-right atrial fistula secondary to an abscess perforation from underlying aortic valve endocarditis](https://scholariq.org/papers/a-rare-case-of-sinus-of-valsalva-right-atrial-fistula-secondary-to-an-abscess/)

## University researchers

- [Ashley Mila](https://scholariq.org/researchers/ashley-mila/)
- [Bradford Ledzian](https://scholariq.org/researchers/bradford-ledzian/)

## University top topics

Showing 8 of 25.

- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)
- [Colorectal Cancer Surgical Treatments](https://scholariq.org/topics/colorectal-cancer-surgical-treatments/)
- [Pancreatitis Pathology and Treatment](https://scholariq.org/topics/pancreatitis-pathology-and-treatment/)
- [Esophageal and GI Pathology](https://scholariq.org/topics/esophageal-and-gi-pathology/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Mechanical Circulatory Support Devices](https://scholariq.org/topics/mechanical-circulatory-support-devices/)
- [Gastrointestinal disorders and treatments](https://scholariq.org/topics/gastrointestinal-disorders-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.